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Abstract Abnormal eating behaviors are frequently
reported in behavioral variant frontotemporal dementia
(bvFTD). The hypothalamus is the regulatory center for
feeding and satiety but its involvement in bvFTD has not
been fully clarified, partly due to its difficult identification
on MR images. We measured hypothalamic volume in 18
patients with bvFTD (including 9 MAPT and 6 C9orf72
mutation carriers) and 18 cognitively normal controls using
a novel optimized multimodal segmentation protocol,
combining 3D T1 and T2-weighted 3T MRIs (intrarater
intraclass correlation coefficients C0.93). The whole
hypothalamus was subsequently segmented into five sub-
units: the anterior (superior and inferior), tuberal (superior
and inferior), and posterior regions. The presence of
abnormal eating behavior was assessed with the revised
version of the Cambridge Behavioural Inventory (CBI-R).
The bvFTD group showed a 17 % lower hypothalamic
volume compared with controls (p\ 0.001): mean 783
(standard deviation 113) versus 944 (73) mm3 (corrected
for total intracranial volume). In the hypothalamic subunit
analysis, the superior parts of the anterior and tuberal
regions and the posterior region were significantly smaller
in the bvFTD group compared with controls. There was a
trend for a smaller hypothalamic volume, particularly in
the superior tuberal region, in those with severe eating
disturbance scores on the CBI-R. Differences were seen
between the two genetic subgroups with significantly
smaller volumes in the MAPT but not the C9orf72 group
compared with controls. In summary, bvFTD patients had
lower hypothalamic volumes compared with controls.
Different genetic mutations may have a differential impact
on the hypothalamus.
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Introduction
Behavioral variant frontotemporal dementia (bvFTD) is a
neurodegenerative disorder characterized by atrophy in the
frontal and temporal lobes and progressive behavioral and
cognitive impairment [1]. Although the majority of cases
are sporadic, about 10–20 % are due to an autosomal
dominant mutation in one of three genes: microtubule-as-
sociated protein tau (MAPT), progranulin (GRN), and
chromosome 9 open reading frame 72 (C9orf72) [2]. One
of the characteristic symptoms of bvFTD is the develop-
ment of abnormal eating behaviors such as hyperphagia,
changes in food preference, and craving for sweet foods,
which are found in the majority of patients [3–5], and have
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been shown to help discriminate bvFTD from Alzheimer’s
disease [6, 7]. However, the neuroanatomical correlates of
abnormal eating behavior in bvFTD are unclear. Previous
studies have suggested the importance of an orbitofrontal–
insular–striatal brain network [8, 9] but one study has also
investigated the role of the hypothalamus, finding a cor-
relation of abnormal eating behavior with lower volumes of
the posterior hypothalamus [10].
The hypothalamus is the regulatory center for feeding
and satiety [11]. It is composed of a number of different
subnuclei and is highly interconnected with other parts of
the central nervous system, particularly the brainstem,
limbic system, and cortex [12, 13]. However, the
hypothalamus is difficult to identify on magnetic resonance
imaging and a detailed anatomical analysis of subdivisions
of the hypothalamus has not yet been performed in bvFTD.
In this study, we aimed to develop an optimized manual
segmentation of the hypothalamus and its subunits using a
novel protocol, and then use this to investigate patterns of
atrophy in bvFTD and specifically whether differences
could be seen in different genetic mutations.
Methods
Participants
Eighteen subjects fulfilling the criteria for the diagnosis of
bvFTD [1] were recruited consecutively from a tertiary
referral cognitive disorders clinic at the National Hospital
for Neurology and Neurosurgery, London, UK. Nine sub-
jects carried a mutation in the MAPT gene and 6 carried a
pathogenic expansion in the C9orf72 gene. The other three
bvFTD subjects tested negative for mutations in MAPT,
C9orf72, and GRN. Eighteen healthy controls were also
recruited. Subjects’ characteristics are summarized in
Table 1. Written informed consent was obtained from all
patients and controls, and the local ethics committee
approved the study. Each patient underwent a standardized
history and neurological examination (including assess-
ment of function using the Frontotemporal dementia Rating
Scale [14] ), neuropsychometry (including the MMSE), and
assessment of behavioral symptoms using the Cambridge
Behavioural Inventory Revised version (CBI-R) [15]. A
subset of four questions on the CBI-R addresses the fre-
quency of abnormal eating behavior scoring 0 for never
occurring, 1 occurring a few times per month, 2 occurring a
few times per week, 3 occurring daily, and 4 occurring
constantly. The questions ask about whether sweet foods
are preferred, whether the subject wants to eat the same
foods repeatedly, whether their appetite is greater than
before and whether there has been a decline in table
manners. The total score for abnormal eating behavior was
converted into percentage of impairment using methods
described previously, where 1–50 % is classified as mild or
moderate, and 51–100 % is classified as severe or very
severe [16].
Imaging parameters
Volumetric T1- and T2-weighted MRI was performed in
all 36 subjects. MRI scans were acquired on a 3T scanner
(Tim Trio, Siemens) with the following sequences:
(i) high-resolution isotropic 3D T1-weighted MPRAGE
(sagittal orientation; TR = 2200 ms, TI = 900 ms, TE =
2.9 ms, flip angle = 10, acquisition matrix = 256 9 256,
and spatial resolution = 1.1 mm) and (ii) high-resolution
isotropic 3D T2-weighted fast spin echo/SPACE (sagittal
orientation; TR = 3200 ms, apparent TE = 105 ms, vari-
able refocusing pulse flip angle to achieve T2-weighting,
acquisition matrix = 256 9 256, and spatial resolution =
1.1 mm).
Development of a hypothalamic segmentation
protocol
A review of hypothalamic anatomy and previously
described hypothalamic segmentation protocols was made
[10, 12, 13, 17–23]. The most detailed segmentation pro-
tocol described was by Schindler et al. [23] which itself
had been designed following a survey of previously pub-
lished protocols. However, in that study, they used 7T T1-
weighted MRIs which tend to be less widely available than
3T MRI. In order to optimize the protocol for 3T MRIs we
made use of a volumetric T2-weighted MRI, acquired at
the same time as the T1 image. By using the software
package NiftyMIDAS (Centre for Medical Image Com-
puting, UCL: http://cmic.cs.ucl.ac.uk/home/software/)
which allows for the simultaneous viewing of different
imaging modalities, we were able to perform a segmenta-
tion of the hypothalamus on registered volumetric T1- and
T2-weighted images allowing better visualization of the
boundaries of the hypothalamus (particularly laterally).
The segmentation protocol of Schindler et al. [23] was
further optimized by reviewing descriptions of hypothala-
mic anatomy [17, 19–21] and criteria from other segmen-
tation protocols [10, 12, 13, 18, 22]. Definitions of
boundaries were made clearer, with greater detail provided
in order to carefully include the hypothalamic nuclei in the
segmentation (in particular the supraoptic, suprachias-
matic, retrochiasmatic nucleus, and the dorsal part of the
arcuate (or infundibular) nucleus), and exclude the fornix.
The protocol is defined in detail in the Supplementary
Material.
2636 J Neurol (2015) 262:2635–2642
123
Methodology for segmentation
Acquired T1-weighted images were initially transformed
into standard space by a rigid registration to the Montreal
Neurological Institute (MNI305) template [23–26].
Acquired T2 images were registered to the MNI305 tem-
plate, using a transformation which combines the ‘‘T2 to T1-
native-space’’ and ‘‘T1 toMNI305-template’’ matrices (both
derived after a six-parameter linear registration) using Nif-
tyReg, revision #418 (Centre forMedical Image Computing,
UCL: http://cmic.cs.ucl.ac.uk/home/software/). Segmenta-
tions were performed manually on coronal slices using
NiftyMIDAS. Segmentations were first performed on the T1
image, and then edited, switching to the corresponding T2-
weighted image which was superimposed on the T1.
Reliability analysis
The reliability of this optimized segmentation protocol was
tested in a sample of ten cognitively normal controls,
scanned using the same MRI protocol as the study partic-
ipants. Hypothalamic structures were segmented twice.
The intraclass correlation (ICC) was computed with a two-
way random effects model, with Dice overlapping coeffi-
cients computed using the Convert3D tool (www.itksnap.
org/pmwiki/pmwiki.php?n=Convert3D.Convert3D). The
intrarater absolute intraclass correlation coefficient (ICC)
was 0.931 (95 % confidence intervals: 0.723–0.983) and
the Dice values were 0.88 (standard deviation 0.02) for
both right and left hypothalamic segmentations, confirming
excellent reliability of the protocol.
Development of a hypothalamic subsegmentation
protocol
In order to investigate subregions of the hypothalamus in
more detail, we adapted a methodology described by
Makris et al. [21]. This uses visible anatomical landmarks
on MRI scans to subsegment the hypothalamus into five
subunits (Fig. 1): (i) the anterior superior hypothalamus (a-
sHyp, which includes the paraventricular nucleus); (ii) the
anterior inferior hypothalamus (a-iHyp, which includes the
supraoptic nucleus); (iii) the superior tuberal hypothalamus
(supTub, which includes the dorsomedial nucleus, the
anterior part of the lateral hypothalamus, and the posterior
part of the paraventricular nucleus); (iv) the inferior tuberal
hypothalamus (infTub, which includes the arcuate (or
infundibular) nucleus, the ventromedial nucleus and the
posterior part of the supraoptic nucleus); and (v) the pos-
terior hypothalamus (posHyp, which includes the posterior
part of the lateral hypothalamus as well as the mammillary
bodies). The detailed protocol for this subsegmentation is
also included in the Supplementary Material.
Methodology for subsegmentation
Using hypothalamic segmentations defined above, delin-
eation of the hypothalamic subunits was also performed
Table 1 Demographic, clinical, and behavioral variables for the bvFTD patients and controls
Controls bvFTD MAPT subgroup C9orf72 subgroup
Number of subjects 18 18 9 6
Gender, male 9 (50 %) 15 (83.3 %) 7 (77.8 %) 5 (83.3 %)
Age at scan (years) 56.4 (14.3) 63.3 (9.1) 59.5 (9.0) 65.1 (7.2)
Disease duration (years) N/A 9.1 (5.5) 8.0 (5.6) 10.8 (6.4)
FRS (/100) N/A 33 (24) 38 (26) 28 (25)
Range 3–73 Range 7–73 Range 3–67
Age at onset (years) N/A 54.3 (8.5) 51.4 (6.3) 54.3 (9.8)
Education (years) 14.2 (3.0) 14.3 (4.3) 14.2 (4.8) 13.3 (3.9)
MMSE (/30) 29.2 (1.2) 25.0 (4.4)* 25.8 (5.0) 24.0 (4.0)*
CBI-R Total (/180) N/A 76.5 (31.8) 76.4 (36.9) 78.7 (33.4)
CBI-R eating disturbance score (/16) N/A 7.7 (3.9) 7.9 (4.2) 8.3 (3.2)
CBI-R: ‘‘prefers sweet foods more than before’’ (/4) N/A 2.5 (1.4) 2.8 (1.6) 2.3 (0.8)
CBI-R: ‘‘wants to eat the same foods repeatedly’’ (/4) N/A 2.1 (1.5) 2.6 (1.5) 1.3 (1.4)
CBI-R: ‘‘her/his appetite is greater, s/he eats more than before’’ (/4) N/A 1.6 (1.4) 1.6 (1.3) 2.0 (1.7)
CBI-R: ‘‘table manners are declining e.g., stuffing food into mouth’’ (/4) N/A 1.6 (1.5) 1.0 (1.1) 2.7 (1.8)
Values denote mean (standard deviation) or n (%)
p values denote significance on Mann–Whitney U or Chi square test
N/A not applicable, FRS frontotemporal dementia rating scale, CBI-R Cambridge Behavioural Inventory Revised version
* p\ 0.05 disease group versus controls
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manually on coronal slices using NiftyMIDAS. This was
performed initially on the T1 image, switching to the
corresponding superimposed T2 image for editing.
Calculation of hypothalamic volumes
Volumes of the whole hypothalamus and its subunits were
automatically computed from the segmentations performed
in NiftyMIDAS and corrected for total intracranial volume
(TIV), which was calculated using the Statistical
Parametric Mapping (SPM) 12b software, version 5953
(www.fil.ion.ucl.ac.uk/spm), running under Matlab R2012a
(Math Works, Natick, MA, USA). The TIV corrected
volume of a specific structure (i.e., the hypothalamus or a
subunit) for each subject ‘‘i’’ was computed as follows:
Structure volumecorrected(i) = Structure volumeraw(i)*-
TIVmean/TIV(i), where ‘‘Structure volumeraw(i)’’ is the raw
value of the structure of the subject ‘‘i,’’ ‘‘TIVmean’’ is the
average TIV of the study group, and ‘‘TIV(i)’’ is the TIV of
the subject ‘‘i.’’
Fig. 1 Segmentation of the
hypothalamic subunits mapped
on a 3T T1-weighted MR image
of a control subject and their 3D
reconstruction on a sagittal
view. a-sHyp anterior superior
hypothalamus, a-iHyp anterior
inferior hypothalamus,
supTub superior tuberal
hypothalamus, infTub inferior
tuberal hypothalamus,
posHyp posterior hypothalamus
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Statistical analyses
Statistical analyses were performed in SPSS software
(SPSS Inc., Chicago, IL, USA) version 12.0 and in R
language v.3.0.2. Differences in demographic, cognitive,
and clinical features as well as brain volumes were tested
with the Mann–Whitney U test for continuous variables
(due to the small sample size and to the non-normal dis-
tribution for all the variables) and Chi square test for
dichotomous variables. For the hypothalamic subunit vol-
umetry (five subunits on either side), a correction for
multiple comparisons was made so that only a threshold of
p\ 0.005 was considered significant.
Results
Demographic characteristics are reported in Table 1: no
significant differences were found in gender, age, or edu-
cation between controls and bvFTD, but the patient group
scored significantly lower on the MMSE. All patients
scored abnormally on the eating disturbance subscale of the
CBI-R: 12 patients scored in the mild to moderate range
(1–50 %) and 6 patients scored in the severe to very severe
range (51–100 %).
No significant differences were seen in demographics,
disease duration, MMSE, FRS, or total CBI-R score
between the MAPT and C9orf72 subgroups. Looking at the
individual eating disturbance subscores of the CBI-R, there
was a trend for higher scores in the MAPT group compared
with C9orf72 in wanting to eat the same foods repeatedly
[mean (SD) score 2.6 (1.3) versus 1.3 (1.4)], with the
opposite trend (higher score in C9orf72) in decline in table
manners [mean (SD) score 2.7 (1.8) versus 1.0 (1.1)].
The bvFTD group showed a 17 % lower total
hypothalamic volume compared with controls (mean (SD)
783 (113) versus 944 (73) mm3, p\ 0.0005, Mann–
Whitney U test) with a similar reduction in both the right
(17 %) and left (18 %) hypothalamus compared with
controls. The MAPT mutation group showed a non-signif-
icant lower right and left hypothalamic volumes on both
sides compared with C9orf72 (10–13 % difference)
(Table 2).
The subsegmentation analysis revealed significant dif-
ferences in the total (left and right combined) volumes of
the superior regions (both anterior and tuberal) as well as
the posterior region (superior tuberal 22 %, posterior 24 %,
and anterior superior region 41 % smaller than controls),
with a similar pattern when looking at the individual right
and left volumes. No significant differences survived cor-
rection for multiple comparisons in the inferior regions
(anterior and tuberal) between the bvFTD group and con-
trols (Table 2).
Looking at the individual MAPT and C9orf72 groups,
only the MAPT mutation carriers showed significant dif-
ferences from controls when corrected for multiple com-
parisons with superior (anterior and tuberal) and posterior
regions being smaller. The C9orf72 group showed a trend
to smaller anterior superior (p = 0.009) and left superior
tuberal regions (p = 0.047). Direct comparisons of the
genetic groups revealed a trend for a smaller right superior
tuberal region (16 %, p = 0.036) and posterior region
(24 %, p = 0.066) in the MAPT group compared with
C9orf72.
In the total bvFTD group, patients who scored in the
severe to very severe range of the CBI-R eating disturbance
subscale had a trend to a lower total hypothalamic volume
[740 (89) mm3] than those in the mild to moderate range
[805 (122) mm3]. This trend for a lower volume in those
scoring in the severe to very severe range was also seen in
the superior tuberal region [205 (36) versus 236 (37) mm3].
Similarly, in both genetic groups, there was a non-signifi-
cantly lower total hypothalamic volume in those scoring
within the severe to very severe range: in the MAPT group
721 (120) versus 773 (147) mm3, in the C9orf72 group 794
(35) versus 884 (60) mm3.
Discussion
Using a novel segmentation protocol for the hypothalamus
and its subunits based upon registered volumetric T1 and
T2 MR images, we have shown that the hypothalamus is
substantially smaller in patients with bvFTD compared
with controls, particularly in the superior and posterior
regions. There was also a trend for a smaller hypothalamus,
particularly in the superior tuberal region, in those who had
severe eating disturbance. Furthermore, there is significant
atrophy in the MAPT mutation group (in superior and
posterior areas), but no significant differences from con-
trols in the C9orf72 mutation group.
Our findings are different from the only previous study
of hypothalamic volume in FTD [10], which found sig-
nificant atrophy in the posterior hypothalamus. Our study
differed from this in a number of aspects, both technical
and clinical. Technically, we used different criteria for the
segmentation of the hypothalamus, in particular, paying
attention to the exclusion of the fornix, and inclusion of the
supraoptic, suprachiasmatic, retrochiasmatic, and arcuate
(or infundibular) nuclei. Furthermore, we were able to
delineate five specific subunits of the hypothalamus,
whereas Piguet et al. [10] used an arbitrary definition of
anterior and posterior regions of the hypothalamus, split-
ting it through the middle coronal plane of their segmen-
tation. Their ‘posterior’ hypothalamus may therefore
include part of the tuberal region as we have defined it in
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this study. Clinically, it is unclear whether the cohorts
overlap as their 18 patients are not genetically defined
unlike the group studied here which contains a significant
number of genetic bvFTD cases. The Piguet cohort has an
earlier mean disease duration (3.3 years versus 9.1 years
here), although disease severity is similar (MMSE 23.9
versus 25.0 here; CBI-R eating disturbance score 6.9 versus
7.7 here). In a separate pathological analysis, they inves-
tigated six tau-positive and six TDP-43 positive FTD cases,
also finding problems more posteriorly, attributing this to
atrophy in the TDP-43 group. However, their tau group
contained only cases with a specific type of tau pathology,
Pick’s disease (a 3-repeat tauopathy), and their TDP-43
group similarly contained only cases with one subtype
(TDP-43 type B). Recent studies have made it clear that
there are large differences both clinically and pathologi-
cally between the different tau and TDP-43 pathological
subtypes (which number at least four in each group), and so
one cannot extrapolate to a significant difference between
‘all TDP-43’ and ‘all tau’ pathology by investigating only
one subtype. Our study suggests that a particular tau group
(MAPT mutations) appear to have significant hypothalamic
volume loss compared with a TDP-43 group (C9orf72
expansions), the opposite finding to Piguet et al. [10].
We found that patients with more severe eating distur-
bance had a trend to lower hypothalamic volumes, partic-
ularly within the superior tuberal region. However, the
differences did not reach statistical significance and so
caution should be attributed to these findings until further
studies are performed. The CBI-R provides only limited
information on the many different types of abnormal eating
behaviors, as only four questions are asked. Eating
behaviors in bvFTD are complex and varied, and include
different aspects, such as carbohydrate craving, overeating,
obsessions for specific foods and oral exploration of
inedible objects, which may not always coexist in an
individual patient [7, 27, 28]. There was a trend for a
difference in the type of eating behaviors exhibited
between the two genetic groups with the MAPT group
scoring higher on wanting to eat the same foods repeatedly
and the C9orf72 group showing a greater decline in table
manners. Further studies are required using more detailed
feeding questionnaires to explore these issues further [7].
This study found significant atrophy in the superior and
posterior subunits of the hypothalamus which contain the
paraventricular nucleus (anterior superior region), dorso-
medial nucleus (superior tuberal region), and lateral
hypothalamic areas (superior tuberal and posterior
Table 2 Volumetry of hypothalamus and its subunits in 18 bvFTD (including nine MAPT and six C9orf72 mutation carriers) and 18 control
subjects
Controls bvFTD % difference
(negative means
smaller in bvFTD
than controls)
MAPT subgroup C9orf72 subgroup % difference
(negative means
smaller in MAPT
than C9orf72)
Hypothalamus—total 944 (73) 783 (113)** -17 756 (133)** 854 (68)* -11
Hypothalamus—right 477 (38) 398 (62)** -17 380 (73)** 436 (41)* -13
Hypothalamus—left 467 (39) 385 (53)** -18 375 (63)** 418 (31)* -10
Anterior superior—total 46 (18) 27 (13)** -41 25 (13)** 25 (11)* 0
Anterior superior—right 22 (10) 13 (7)** -43 12 (6)* 12 (7)* 0
Anterior superior—left 23 (9) 14 (6)** -38 13 (7)* 14 (5)* -7
Anterior inferior—total 30 (18) 18 (8) -40 20 (8) 17 (8) ?18
Anterior inferior—right 15 (10) 9 (4)* -40 8 (4) 8 (4) 0
Anterior inferior—left 15 (8) 10 (5) -34 11 (5) 8 (5) ?38
Superior tuberal—total 289 (54) 225 (38)** -22 213 (41)** 251 (30) -15
Superior tuberal—right 145 (30) 114 (20)** -21 108 (18)**,^ 129 (19) -16
Superior tuberal—left 144 (24) 111 (20)** -23 105 (25)** 122 (12)* -14
Inferior tuberal—total 317 (38) 314 (37) -1 317 (48) 322 (22) -2
Inferior tuberal—right 162 (20) 158 (20) -2 158 (26) 163 (13) -3
Inferior tuberal—left 155 (22) 156 (19) ?1 159 (23) 159 (11) 0
Posterior—total 263 (49) 199 (59)** -24 181 (60)** 239 (49) -24
Posterior—right 133 (27) 104 (34)* -22 94 (35)** 124 (29) -24
Posterior—left 130 (24) 95 (27)** -26 87 (26)** 115 (26) -24
Volumes are corrected for TIV. Values denote mean (standard deviation) volumes in mm3. p values denote significance on Mann–Whitney U test
* p\ 0.05, ** p\ 0.005 disease group versus controls; ^ p\ 0.05 MAPT versus C9orf72 subgroups. Significance threshold was set at
p\ 0.005 to correct for multiple comparisons
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regions). These subnuclei are all involved in important
aspects of appetite regulation and contain neuropeptide-
expressing neurons and neuropeptide receptors [20, 29–
32]. Interestingly, the inferior tuberal area was not atrophic,
an area which contains the arcuate (or infundibular) and
ventromedial nuclei. The arcuate nucleus is the primary
target of metabolic and hormonal signals from the
periphery, with important connections to other nuclei in the
hypothalamus particularly the paraventricular nucleus [30].
This suggests that appetite abnormalities in bvFTD could
be due to changes in neuropeptides (or neuropeptide
receptors) within the superior and posterior areas of the
hypothalamus and/or from disruption of pathways from the
arcuate nucleus to other areas of the hypothalamus. As
there is differential neuropeptide expression within these
nuclei, different neuropeptide levels should be impaired
compared with others in bvFTD: such a hypothesis has yet
to be explored.
There was a trend for greater posterior involvement in
the MAPT group compared with the C9orf72 group, with
both left and right posterior regions 24 % smaller in the
MAPT group. As well as the posterior part of the lateral
hypothalamus, the posterior region contains the mammil-
lary bodies, which are connected to the amygdala and
hippocampus, areas known to be major areas of atrophy in
patients with MAPT mutations [33]. Given this finding,
future studies should further investigate the relationship of
memory impairment in these patients to hypothalamic
atrophy.
In summary, bvFTD patients had smaller hypothalamic
volumes compared with controls, with atrophy localized to
subnuclei regulating food intake, reward and perception of
satiety, and related to the severity of the eating disturbance.
Moreover, different genetic mutations seem to have a dif-
ferential impact on the hypothalamus, although further
studies in larger genetic and pathological series are
required to confirm this. The structural and functional
connections of the hypothalamus should be further
explored in bvFTD, particularly how they relate to the
orbitofrontal-insular-striatal reward network previously
identified. Lastly, the results of this study suggest testable
hypotheses of the role of different neuropeptides in
impaired appetite regulation in bvFTD.
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